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London, United Kingdom; Florence, Novara, and Milan, Italy; and SingaporeObjectives The aim of this study was to compare the acute performance of the PLLA ABSORB
bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, California) with second-generation
metal drug-eluting stents (DES) in complex coronary artery lesions.
Background Thick polymer-based BVS have different mechanical properties than thin second-
generation DES. Data on the acute performance of BVS are limited to simple coronary lesions treated in
trials with strict inclusion criteria.
Methods Fifty complex coronary lesions (all type American College of Cardiology/American Heart
Association B2-C) treated with a BVS undergoing a ﬁnal optical coherence tomography (OCT)
examination were compared with an equal number of matched lesions treated with second-
generation DES. The following stent performance indexes were assessed with OCT: mean and minimal
area, residual area stenosis (RAS), incomplete strut apposition (ISA), tissue prolapse, eccentricity index,
symmetry index, strut fracture, and edge dissection.
Results One hundred lesions from 73 patients were analyzed. A higher balloon diameter/reference
vessel diameter ratio was used for predilation in the BVS group (p < 0.01). Most of the BVS and
DES were post-dilated with short noncompliant (NC) balloons of similar diameter. OCT showed in the
BVS group a higher tissue prolapse area (p ¼ 0.08) and greater incidence of ISA at the proximal edge
(p ¼ 0.04) with no difference in the overall ISA. The RAS was 20.2% in the BVS group and 21.7% in the
DES group (p ¼ 0.32). There was no difference in the eccentricity index. The minimal and mean lumen
areas were similar in the 2 groups. Two cases of strut fractures occurred after the BVS, whereas none
was observed in the DES.
Conclusions Based on OCT, the BVS showed similar post-procedure area stenosis, minimal lumen
area, and eccentricity index as second-generation DES. The different approach for lesion preparation
and routine use of OCT guidance during BVS expansion may have contributed to these results.
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742In daily clinical practice interventional cardiologists face
complex coronary lesions that are often calciﬁed and long
and involve bifurcations. Optimal mechanical stent perfor-
mance is crucial in the treatment of these lesions, and the
alloy-based thin-strut second-generation drug-eluting stents
(DES) are considered the gold standard for the treatment of
these complex coronary artery lesions (1,2). The conform-
ability and radial strength of second-generation DES allow
optimal deployment in long tapered lesions and bifurcations
because of the possibility to post-dilate the stent and im-
prove expansion and apposition (3). Furthermore, the high
radial strength of modern DES is crucial to counteract
the acute plaque recoil frequently observed in ﬁbrocalciﬁc
lesions.
Bioabsorbable drug-eluting scaffolds (BVS) (ABSORB,
Abbott Vascular, Santa Clara, California) have emerged asAbbreviations
and Acronyms
BVS = bioresorbable vascular
scaffold(s)
DES = drug-eluting stent(s)
ISA = incomplete strut
apposition
IVUS = intravascular
ultrasound
LAD = left anterior
descending artery
NC = noncompliant
OCT = optical coherence
tomography
PCI = percutaneous coronary
intervention
QCA = quantitative coronary
angiography
RAS = residual area stenosisa potential major breakthrough
for treatment of coronary artery
lesions. In principle, the need for
vessel scaffolding and drug de-
livery is temporary, rendering a
permanent stent superﬂuous once
the vessel has healed and the pro-
cesses of recoil and hyperplasia
have ended. Conventional perma-
nent stent implantation precludes
future surgical revascularization,
complicates recrossing into side
branches, eliminates reactive vas-
omotion, impairs noninvasive im-
aging, and exposes patients to the
risk of very late thrombosis. These
long-term limitations of conven-
tional stents may be overcome to
a degree by using biodegradable
scaffolds (4). However, the me-
chanical properties of polymer-
based scaffolds substantially differ
from those of metal stents, and thus far, available data on the
acute mechanical performance of bioresorbable vascular scaf-
folds (BVS) are limited to the treatment of relatively simple
coronary lesions in the context of early-stage clinical trials (5,6).
The aim of this study was to compare the acute per-
formance of BVS with that of second-generation DES in
the treatment of complex coronary artery lesions using
optical coherence tomography (OCT) to assess appropriate
stent deployment (7).
Methods
Study population. The study population comprised
consecutive patients undergoing percutaneous coronary
intervention (PCI) of complex coronary lesions with stent
optimization under OCT guidance, which is our routine
RVA = reference vessel areafor complex lesion stenting (8). From September 2012
until May 2013, patients treated with a BVS at the Royal
Brompton Hospital (London, United Kingdom) and Co-
lumbus Hospital (Milan, Italy) were prospectively enrolled.
Of 148 patients with complex lesions treated with second-
generation DES at the Royal Brompton Hospital between
January 2009 and May 2013 and optimized using post-
deployment OCT examination (DES group), we selected
an equal number of lesions with angiographic character-
istics matched to those in the BVS group. The 1:1 selection
without replacement has been performed according to the
following stepwise selection criteria: lesion length, vessel
reference diameter, ostial position, bifurcation involvement,
severe or moderate calciﬁcations, and chronic total occlusion.
All patients provided signed informed consent for stent
deployment and OCT guidance. The devices used in the
DES group were the everolimus-eluting Xience Pro and Prime
(Abbott Vascular), Promus Element and Premiere stents
(Boston Scientiﬁc, Natick, Massachusetts), and the zotar-
olimus-eluting Resolute Integrity stent (Medtronic Vascular,
Santa Rosa, California). BVS were not used in patients pre-
senting with acute ST-segment elevation myocardial infarc-
tion, coronary bifurcations with a default 2-stent strategy,
a target lesion in a vessel with a reference diameter<2.5 mm,
and, because of the impossibility of performing serial
OCT examinations, an estimated glomerular ﬁltration rate
<30 ml/min, or aorto-ostial lesions. The main inclusion
criteria in the BVS group used to deﬁne the lesion
complexity were length >24 mm, moderate to heavy calci-
ﬁcation, ostial position (different from aorto-ostial RCA
and LM ostium which were excluded), bifurcation in-
volvement, and chronic total occlusion.
Quantitative coronary angiography analysis and lesion
characterization. Quantitative coronary angiography (QCA)
was performed using a computer-based QCA system (CAAS
QCA-2D system, Pie Medical Imaging BV, Maastricht, the
Netherlands) with the dye-ﬁlled catheter used for calibration.
For each lesion, the following QCA parameters were
measured: minimal lumen diameter, reference vessel diameter
(RVD), percentage of area stenosis, and lesion obstruction
length. The largest balloon diameter and maximal inﬂation
pressure during lesion predilation were recorded and used to
calculate the balloon/artery ratio (mean inﬂated balloon
diameter/mean reference vessel diameter). In addition, we
assessed the presence of angiographic calciﬁcation.
Treatment procedures. In both groups, lesions were treated
with pre-dilation using conventional semicompliant or NC
balloons. The use of additional devices (cutting balloons or
rotablator) was left to the operator’s discretion. Unlike for
DES, deployment of the BVS was performed using slow
balloon inﬂation (i.e., 2 atm per 10 s) without exceeding the
rated pressure indicated in the product instructions for use.
Post-dilation with short NC balloons was systematically
performed both for the BVS and DES, using OPN NC
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743balloons (SIS Medical AG, Winterthur, Switzerland) when
pressures >30 atm were required (9). Attention was paid to
avoid reaching a maximal balloon diameter beyond the
recommended rupture point of the BVS by strictly following
the NC balloon compliance chart. In case of lesions
involving a bifurcation, ﬁnal optimization with sequential
dilation was preferentially adopted for BVS. Conversely, for
DES ﬁnal kissing balloon was the default strategy.
OCT assessment was performed in most cases before stent
deployment and repeated when stent expansion was con-
sidered optimal angiographically. In the event of suboptimal
deployment as assessed with OCT, further post-dilation was
performed or additional BVS/DES were implanted, after
which a ﬁnal OCT scan was performed and used for the
study analysis.
OCT performance. Frequency domain OCT was performed
using the C7 system or the Ilumien Optis system (St. Jude
Medical, Minneapolis, Minnesota). For both systems,
DragonFly or DragonFly 2 imaging catheters (St. Jude
Medical) were used. Automatic pullbacks were performed at
20 mm/s during contrast injection at a rate of 3 to 5 ml/s
using a power injector. The OCT catheter was inserted
distal to the treated segment, and the pullback continued
until either the guiding catheter was reached or the maximal
pullback length (5.5 cm with the C7 system and 7.4 cm with
the Ilumien Optis system) was completed. Two sequential
pullbacks were combined to enable assessment of the entire
stented segment when required.
OCT ofﬂine analysis. The OCT measurements were
repeated ofﬂine using the LightLab Imaging workstation
(St. Jude Medical). The analysis of contiguous cross sections
was performed at 1-mm intervals within the entire stented
segment and at 5 mm proximal and distal to the stent to
measure the proximal and distal reference vessel area (RVA)
and to identify dissections. RVA was calculated as the mean
of the 2 largest luminal areas 5 mm proximal and distal to
the DES/BVS edge (7). In case of the absence of a mean-
ingful proximal or distal segment due to the ostial location
of the lesion or the presence of a large side branch at the
stent edge, only a proximal or distal reference cross section
was used to calculate the RVA (10). Stent edge dissection
was deﬁned as a disruption of the vessel luminal surface at
the stent edge with visible ﬂap. Stent fracture was suspected
in the presence of isolated struts lying unapposed in the
lumen with no connection or overridden by the contiguous
stent struts. For each cross section analyzed, the area, mean,
and maximal and minimal diameter of the stent were auto-
matically contoured and measured by the analysis system,
with manual correction as appropriate (4).
For analysis of the BVS, which are transparent to the
near-infrared light of the OCT catheter, incomplete strut
apposition (ISA) was deﬁned as presence of struts sepa-
rated from the underlying vessel wall (7). For metal
DES, inducing posterior dropout, struts were consideredmalapposed when the axial distance between the strut’s
surface and the luminal surface was greater than the strut
thickness (11). Tissue prolapse was deﬁned as the presence
of tissue protruding between stent struts extending into the
lumen as a circular arc connecting adjacent struts (4).
The following quantitative parameters were calculated for
each stent (5,7,11,12): the percentage of the ISA, calculated
as a ratio of the total number of struts observed at 1-mm
intervals; the percentage of stents with ISA at the proximal
and distal edges deﬁned as the last 5 mm of the stent before
the stent end; the ISA area (mm2) (only for BVS) measured
as illustrated in Figure 1; the tissue prolapse area (mm2)
calculated as the difference between the stent area and the
lumen area as illustrated in Figure 1; the percentage of RAS
calculated as: [1  (minimal lumen area/RVA)  100], as
illustrated in Figure 2; the eccentricity index, the ratio be-
tween the minimal and the maximal diameter. For each stent
both the mean and minimal eccentricity index were com-
puted (illustrated in Fig. 2); the symmetry index, deﬁned as:
(maximal stent diameterminimal stent diameter)/(maximal
stent diameter).
Follow-up. Clinical follow-up was obtained at w1 month
after the procedure and every 6 months after by direct
clinical examination.
Statistical analysis. Descriptive statistics (means and SDs
for continuous variables with normal distribution and fre-
quency and relative frequency for categorical variables) were
computed according to treatment type (BVS or DES).
Comparison between groups for continuous variables was
performed by an unpaired t test (in case of parametric distri-
bution) or the Mann-Whitney U test (in case of nonpara-
metric distribution), as appropriate. Univariate associations
between treatment type and coronary lesion features were
examined using 2-way contingency tables. Signiﬁcance of
associations were assessed using the chi-square test or the
Fisher exact test, as appropriate. For all the statistical tests
used, a p value <0.05 was required to reject the null hypoth-
esis. The statistical analysis was performed using the SPSS
statistical software package version 16.0 (IBM Corporation,
Somers, New York).
Results
Population. Fifty lesions treated with 63 BVS in 35 patients
were matched with 50 lesions treated with 61 second-
generation DES in 38 patients. Baseline clinical characteris-
tics of the patients are shown in Table 1. There were
no signiﬁcant differences in the 2 groups, with a minority
of patients (4.1%) presenting with unstable angina as an
indication for the PCI procedure.
Angiographic and QCA baseline lesion characteristics are
summarized in Table 2. The left anterior descending artery
(LAD) was the target vessel in a large proportion of cases
in both groups (BVS, n ¼ 34, 68%; DES, n ¼ 25, 50%;
Figure 1. Qualitative and Quantitative Assessment of OCT Characteristics
(A) An example of incomplete strut apposition (ISA). There are 4 malapposed struts between 10 and 12 o’clock position in A1, with 1 more malapposed strut probably
concealed by the wire shadow (asterisk). In a bioresorbable vascular scaffold (BVS), the possibility of identifying the abluminal border of the struts allows evaluation of
the ISA area, as indicated in A2. (B) Tissue prolapse. In the presence of tissue prolapse, deﬁned as tissue protruding between the struts, the prolapse area was
measured as the difference between the stent and lumen area (highlighted in green in B2). (C) An example of edge dissection (arrow) distal to the BVS. Because of the
large lumen size and small circumferential extension of dissection, no treatment was performed. (D) A BVS strut fracture. This cross section at the level of the left
anterior descending artery (LAD) D1 carina shows a scaffold pattern irregularity with an overhanging strut (arrow) in the center of the vessel without obvious
connection to the expected/adjacent strut pattern. In this patient before this ﬁnal optical coherence tomography (OCT) study, the BVS was rewired to dilate the ostium
of D1 with a 2.5-mm semicompliant balloon.
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744p ¼ 0.11). As expected, based on the inclusion criteria, all
lesions met the American College of Cardiology/American
Heart Association classiﬁcation criteria for B2 or C lesions.
There were no signiﬁcant differences in the presence ofcalciﬁcation, ostial involvement, and bifurcation involve-
ment. Reference vessel diameter, minimal lumen diameter,
and lesion length, as assessed with QCA, were also similar
(lesion length: BVS, 24.7  14.2 mm; DES, 25.1  10.6
Figure 2. Residual Area Stenosis and Eccentricity Index
The proximal and distal RVAs (A,D) were used to calculate the reference vessel area. The ratio between minimal lumen area and RVA was used to compute the residual
area stenosis (C). (B) An example of evaluation of the minimum eccentricity index.
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745mm; p ¼ 0.86). Two chronic total occlusions were suc-
cessfully treated in the BVS group and 4 in the DES group.
Procedural characteristics. Sixty-three BVS and 61 DES
were implanted with a similar number of stents per lesion in
the 2 groups (BVS, 1.3  0.6; DES, 1.2  0.5; p ¼ 0.28).
Xience Prime was the most frequently used DES (n ¼ 35,
57.4%), whereas Promus Element or Premiere and Resolute
Integrity stents were used in 16 (26.2%) and 10 (16.4%) of
cases, respectively. The median stent length was 28.0 mm
(interquartile range: 20.5 to 28.0 mm) in the BVS group and
28.0 mm (interquartile range: 20.0 to 38.0 mm) in the DES
group (p ¼ 0.42). As shown in Table 3, a higher balloon
diameter/mean reference vessel diameter ratio was used for
predilation in the BVS group (BVS, 1.1  0.1; DES, 0.9 
0.1; p < 0.01), with signiﬁcantly higher pressure inﬂationfor both pre- and post-dilation. NC balloons were more
frequently used for lesion preparation in the BVS group.
Sequential dilation was the only technique used for bifur-
cation optimization in the BVS group, whereas kissing
balloons were consistently used in the DES group (13).
OCT ﬁndings. OCT ﬁndings are summarized in Table 4. A
total of 2,953 cross sections and 24,352 struts were analyzed.
The mean and minimal lumen area were similar in the
2 groups. The incidence of RAS >20% was not statistically
signiﬁcant different in the BVS group (BVS: n ¼ 25, 39.7%;
DES: n ¼ 26, 42.6%; p ¼ 0.85), and there was no difference
in the mean RAS (BVS, 20.2  7.5%; DES, 21.7  9.9%;
p ¼ 0.32). There was a higher incidence of ISA at the
proximal edge in the BVS group (BVS: n ¼ 25, 39.7%;
DES: n ¼ 14, 23.0%; p ¼ 0.04) but no difference in the
Table 2. Angiographic and QCA Lesion Characteristics (N ¼ 100)
BVS (n ¼ 50) DES (n ¼ 50) p Value
Target vessel 0.11
LAD 34 (68.0) 25 (50.0)
LCX 4 (8.0) 11 (22.0)
RCA 11 (22.0) 14 (28.0)
Venous graft 1 (2.0) 0 (0.0)
AHA/ACC lesion classiﬁcation 0.38
B2 18 (36.0) 13 (26.0)
C 32 (64.0) 37 (74.0)
Moderate to heavy calciﬁcation* 31 (62.0) 37 (74.0) 0.28
Chronic total occlusion 2 (4.0) 4 (8.0) 0.67
Ostial involvement 7 (14.0) 5 (10.0) 0.76
Bifurcation involvement 17 (34.0) 23 (46.0) 0.30
Side branch RVD (with QCA), mm 2.3 (0.3) 2.4 (0.4) 0.53
Medina classiﬁcationy 0.88
1,1,1 5 (29.4) 6 (26.1)
1,1,0 9 (59.2) 13 (56.5)
1,0,0 3 (17.6) 4 (17.4)
In-stent restenotic lesion 6 (12.0) 3 (6.0) 0.48
QCA main branch analysis
RVD, mm 2.7 (0.4) 2.7 (0.3) 0.86
MLD, mm 0.8 (0.4) 0.7 (0.3) 0.16
AS, % 83.7 (15.2) 86.9 (11.6) 0.25
Lesion length, mm 24.7 (14.2) 25.1 (10.6) 0.86
Values are n (%). *Angiographic assessment of the degree of calciﬁcation. yOnly Medina
combinations represented in the study population are reported.
AS ¼ area stenosis; LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery;
MLD ¼ minimal lumen diameter; QCA ¼ quantitative coronary angiography; RCA ¼ right
coronary artery; RVD ¼ reference vessel diameter; other abbreviations as in Table 1.
Table 1. Patient Characteristics (N ¼ 73)
BVS (n ¼ 35) DES (n ¼ 38) p Value
Age, yrs 59.7 (11.2) 65.2 (10.7) 0.64
Male sex 27 (77.1) 31 (81.6) 0.77
Hypertension 26 (74.3) 23 (60.5) 0.22
Hypercholesterolemia 24 (71.4) 23 (60.5) 0.45
Diabetes 12 (34.3) 11 (28.9) 0.80
Current smokers 17 (48.6) 14 (36.8) 0.35
Previous PCI 14 (40.0) 8 (21.1) 0.13
Previous myocardial infarction 7 (20.0) 4 (10.5) 0.33
Previous CABG 1 (2.9) 3 (7.9) 0.61
Clinical indication 0.61
Stable angina 34 (97.1) 36 (94.7)
Unstable angina 1 (2.9) 2 (5.3)
No. of diseased vessels 0.72
1 14 (40.0) 17 (44.7)
2 14 (40.0) 16 (42.1)
3 7 (20.0) 5 (13.2)
Values are n (%).
BVS ¼ bioresorbable vascular scaffold(s); CABG ¼ coronary artery bypass graft; DES ¼ drug-
eluting stent(s); PCI ¼ percutaneous coronary intervention.
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746overall percentage of ISA (BVS, 1.7  2.1%; DES, 1.9 
2.4%; p ¼ 0.62) and number of stents with ISA (BVS:
n ¼ 33, 52.4%; DES: n ¼ 39, 63.9%; p ¼ 0.19) (Fig. 3).
The mean and minimal eccentricity index and the
symmetry index were similar in the 2 groups.
In the BVS group, there was a trend toward a higher
prolapse area (BVS, 1.5  2.4 mm2; DES, 0.8  1.2 mm2;
p ¼ 0.08), but this did not have a signiﬁcant impact on the
ﬁnal lumen area, which was similar in both groups. OCT
analysis showed 12 edge dissections (BVS: n ¼ 5, 7.9%;
DES: n ¼ 7, 11.5%; p ¼ 0.55), which were not apparent
on the angiogram. None of these required further stent
implantation. In the DES group, strut fractures were not
observed, whereas in 2 patients in the BVS group, 2 stent
fractures developed. In both cases, the lesions were localized
in the LAD across the origin of a diagonal branch, and
the scaffolds were recrossed to optimize the results with
sequential dilation.
Clinical follow-up. Clinical follow-up data were available for
all BVS patients and for 31 patients (89.5%) in the DES
group. The mean duration of follow-up was signiﬁcantly
different in the 2 groups (BVS, 8.5  2.8 months; DES,
17.3  8.7 months; p < 0.01). One patient treated with
2 BVS in the proximal, mid, and distal LAD presented
2 months later with acute coronary syndrome due to a
critical lesion in a diagonal branch not treated with stenting
during the index PCI, although the 3 previously implanted
BVS were patent. One insulin-dependent diabetic patient
with a proximal LAD BVS required a coronary artery bypass
graft after 9 months because of diffuse distal disease pro-
gression (no in-stent restenosis). Further details providedin the Online Appendix. In the DES group, 2 patients
(5.3%) underwent PCI due to in-stent restenosis at 14 and
24 months, respectively, after the baseline PCI.
Discussion
This is the ﬁrst OCT study to compare acute stent per-
formance between a BVS and second-generation DES in
complex coronary artery lesions.
The OCT indexes used in our study are widely accepted
as criteria for determining optimal stent deployment
(7,12). These were derived from intravascular ultrasound
(IVUS) criteria used for the evaluation of metal stents and
shown to correlate with 1-year clinical outcomes (stent
thrombosis and restenosis) after implantation of a BMS
and ﬁrst-generation DES (14,15). In particular, a RAS
>20% and an absolute minimal cross-sectional area <5.5
or 6.0 mm2 were previously correlated with acute/subacute
stent thrombosis and restenosis (16,17). In our study, the
mean RAS and absolute MLA in both the BVS and sec-
ond-generation DES were close to these cutoff levels. The
thresholds deﬁned in these early IVUS evaluations of DES
were derived from analyses of trials including short-type
Table 4. Optical Coherence Tomography Findings (N ¼ 124)
BVS (n ¼ 63) DES (n ¼ 61) p Value
Mean stent area, mm2 7.3 (2.3) 7.5 (1.6) 0.51
Minimal stent area, mm2 5.9 (1.9) 5.8 (1.5) 0.67
Mean lumen area, mm2 7.2 (2.2) 7.4 (1.6) 0.40
Minimal lumen area, mm2* 5.8 (1.9) 5.8 (1.5) 0.97
Median stent diameter, mm 2.9 (0.5) 3.1 (0.3) 0.33
Minimal stent diameter, mm 2.7 (0.4) 2.8 (0.5) 0.46
Maximal stent diameter, mm 3.2 (0.5) 3.3 (0.4) 0.52
Percentage RAS 20.2 (7.5) 21.7 (9.9) 0.32
Stent with RAS >20% 25 (39.7) 26 (42.6) 0.85
Median eccentricity index 0.85 (0.08) 0.86 (0.04) 0.45
Minimum eccentricity index 0.73 (0.09) 0.72 (0.12) 0.73
Symmetry index 0.33 (0.08) 0.38 (0.37) 0.35
ISA analysis
Percentage of malapposed struts 1.7 (2.1) 1.9 (2.4) 0.62
Stent with at least 1 ISA 33 (52.4) 39 (63.9) 0.19
Stent with ISA at the proximal edge 25 (39.7) 14 (23.0) 0.04
Stent with ISA at the distal edge 5 (7.9) 7 (11.5) 0.56
ISA area, mm2 (for BVS only) 1.0 (1.2) NA NA
Maximal ISA length, mmy 0.4 (0.2) 0.3 (0.2) 0.09
Prolapse area, mm2 1.5 (2.4) 0.8 (1.2) 0.08
Fracture 2 (3.2) 0 (0.0) 0.49
Edge dissection 5 (7.9) 7 (11.5) 0.55
Values are n (%). *Minimal lumen area within the scaffold. yOnly for stent with ISA.
RAS ¼ residual area stenosis; ISA ¼ incomplete strut apposition; NA ¼ not assessed;
other abbreviations as in Table 1.
Table 3. Procedural Characteristics (N ¼ 100)
BVS (n ¼ 50) DES (n ¼ 50) p Value
Maximal diameter balloon
pre-dilation, mm
3.0 (2.5–3.1) 2.5 (2.5–3.0) <0.01
Maximal pre-dilation balloon
inﬂation, atm
18.7 (3.5) 15.1 (3.8) <0.01
Balloon/artery ratio 1.1 (0.1) 0.9 (0.1) <0.01
NC balloon pre-dilation 50 (100.0) 37 (87.0) <0.01
Cutting balloon predilation 6 (12.0) 3 (6.0) 0.48
Rotablator 2 (4.0) 2 (4.0) NA
Stent diameter, mm 3.0 (3.0–3.5) 3.0 (3.0–3.5) 0.94
Stent length, mm 28.0 (20.5–28.0) 28.0 (20.0–38.0) 0.42
No. of stents per lesion, 1/2/3 37/9/4 40/9/1 0.28
Maximal post-dilation balloon
diameter, mm
3.5 (3.0–3.5) 3.5 (3.0–3.5) 0.60
Maximal post-dilation balloon
inﬂation, atm
21.3 (4.9) 17.1 (3.7) <0.01
Kissing balloon, MV/SB 0 (0.0) 4 (8.0) 0.11
Sequential dilation, MV/SB 8 (16) 0 (0.0) <0.01
Values are median (interquartile range) or n (%).
NA ¼ not assessed; NC ¼ noncompliant; MV ¼ main vessel, SB ¼ side branch; other
abbreviations as in Table 1.
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747A-B1 lesions. Results for more complex lesions are limited
and expected to be worse because of the higher plaque
burden and resistance. In a previous study by our group,
calciﬁed lesions with OCT were analyzed, and a higher
RAS and a greater ISA than in simple lesions were
observed (18). The use of OCT rather than IVUS may
explain part of the difference. By virtue of its higher res-
olution, OCT can deﬁne more precisely the lumen area
contours and quantify plaque prolapse, which is frequently
concealed by strut artifacts when using IVUS. Moreover,
OCT has been shown to measure lower absolute areas than
IVUS, both in vitro and in vivo (19). The areas observed in
the complex lesions of our BVS group were very similar to
those reported in an OCT substudy of the ABSORB trial
cohort B (10) in which relatively simple lesions were
treated. Also the type of metal stents used may play a role.
The thick stainless steel struts of ﬁrst-generation DES
may create a rough cobblestone surface with a higher risk
of thrombosis but have less recoil than the thin struts
of second-generation stents constructed using alloys such
as cobalt and platinum chromium (3,20).
The lack of difference between the BVS and second-
generation DES in mean and minimal values of relative
and absolute stent area is the true novel ﬁnding of the cur-
rent study. This could be expected based on in vitro studies
conducted by the industry for registration and on small
comparative studies with IVUS between the BVS
and Xience V stents (21,22). The observations made using
OCT in the current study support the application of BVS
beyond the current indications. These results suggest that a
satisfactory BVS expansion can also be achieved in complexcoronary lesions, at least when appropriate lesion preparation
and deployment under OCT guidance is performed.
The clinical relevance of ISA is controversial. Previous
IVUS studies using ﬁrst-generation DES to treat simple
lesions (23,24) showed no value in predicting late adverse
events. However, an IVUS study performed at the time of
acute stent thrombosis showed a higher incidence of ISA
compared with controls (25). In our study, no difference
was observed in the absolute number and percentage of
malapposed struts between the BVS and DES, with the
latter being considerably lower than shown in previous
OCT studies of predominantly ﬁrst-generation DES (26).
Repeated OCT examinations in both groups, prompted
additional dilations at high pressure with properly sized
balloons, probably explain the low prevalence of ISA in the
complex lesions treated in this study. Some malapposition
was still observed in pre- or post-stenotic ectasic segments,
in eccentric calciﬁc lesions, and at bifurcations, although
in many cases, this was impossible to correct completely
despite serial or kissing balloon dilation (27,28). In the BVS
group, we observed a more frequent malapposition at the
proximal stent edge (39.7% of BVS vs. 23.0% of DES, p ¼
0.04), which may have procedural relevance because
struts protruding into the lumen complicate the advance-
ment of balloons or additional distal stents. The greater
Figure 3. Main Optical Coherence Tomography Results of the BVS Versus the DES
Histograms show a similar mean and minimal in stent lumen area (A), percentage of residual area stenosis, and stent with residual area stenosis >20% (B), and overall
percentage of malapposed struts (C). A higher incidence of proximal strut malapposition at the proximal edge was observed in the BVS (D). BVS ¼ bioresorbable
vascular scaffold(s); DES ¼ drug-eluting stent(s).
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748conformability of second-generation DES compared to the
BVS may explain these ﬁndings because extreme attention
was paid to post-dilation with appropriately sized balloons
that covered the proximal edge of the BVS, which is an-
giographically well visualized by the radiopaque platinum
proximal marker. A potential advantage of the bioresorbable
technology over the metal device is that any acute ISA
resolves after the process of strut degradation has been
completed, although this process may require as long as
2 years (29).
Gomez-Lara et al. (10) performed an OCT substudy of
the ABSORB trial Cohort B, in which only 3-mm diameter
BVS devices were deployed. These investigators found a
higher incidence of malapposed struts in vessels with a
maximal diameter >3.3 mm. These data emphasize the
importance of correct vessel size measurement to select the
appropriate BVS diameter. Based on this observation, we
recommend oversizing the BVS as much as 0.5 mm above
the smallest reference vessel diameter, which allows better
adaptation, especially in tapered vessels.
The amount of tissue prolapse was slightly higher with
the BVS than the DES. This may be explained bydifferences in stent design and the lower number of struts
per cross section in BVS compared with second-generation
DES. In our population of stable lesions, the greater plaque
prolapse was not clinically relevant because it did not alter
the ﬁnal mean and minimal lumen area. Moreover, the
thicker struts of the BVS mean that the prolapsed plaque is
always surrounded by the stent struts with less herniation
into the vessel lumen and a smoother surface compared
with thinner strut DES (Fig. 1). However, tissue prolapse
is more prominent in unstable or thrombus-containing
lesions (30), and in this setting, the scaffolding properties
of the BVS might be insufﬁcient to counteract plaque
prolapse.
A very similar post-procedural stent geometry was
observed in both BVS and DES. The mean and minimal
values of the eccentricity index were similar in the 2 groups.
Brugaletta et al. (22) reported a higher symmetry index
value for the BVS, whereas the eccentricity index was
signiﬁcantly lower in the BVS compared with the DES
(0.85  0.08 vs. 0.90  0.06, p < 0.01). In the current
study, the minimal eccentricity index was lower for both
the BVS and DES compared with the ﬁndings of Brugaletta
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749et al. (22), likely a consequence of including more complex
lesions.
Study limitations. The acute mechanical performance of the
BVS observed in this study cannot be taken for granted
unless implantation is performed with the same meticulous
attention to lesion preparation, systematic sizing of the BVS
to the proximal reference vessel diameter, and high pressure
post-dilation. Scaffold implantation was performed under
OCT guidance. Therefore, our results cannot be automati-
cally applicable to conventional angiographic BVS deploy-
ment. The main limitation of this study is the use of a
historical nonrandomized control group with a limited
sample size and follow-up duration, which precludes any
meaningful long-term clinical comparison of the rare long-
term adverse events observed in patients treated with mod-
ern DES. A matched cohort as a control population is
frequently used in the evaluation of novel devices and is
certainly of value for the assessment of the mechanistic
response. There was no signiﬁcant difference observed in key
parameters of acute stent performance in the 2 subgroups
treated with a BVS or DES. However, adjustments for
multiple correlated observations were not made, and deﬁn-
itive proof of noninferiority would require a prospective,
randomized study with a larger study population. Prospec-
tive, randomized, controlled trials are required to determine
whether the acute mechanical performance of a BVS
observed in the current study can be translated into an
improved long-term clinical outcome in patients with com-
plex coronary lesions treated by PCI. The short follow-up
duration provided in the BVS group may be inappropriate
to observe disease progression and late target lesion failure.
Finally, although no new Q waves or ST-segment elevation
or prolonged chest pain were observed, we did not consis-
tently measure post-procedural troponin in all patients.
Conclusions
We report our early experience of treating complex coronary
lesions using a BVS. Systematic aggressive lesion prep-
aration, sizing of a BVS to the proximal reference vessel
diameter, high pressure post-dilation, and use of OCT for
optimization enable us to achieve post-procedural area ste-
nosis, minimal lumen area, and an eccentricity index similar
to that of contemporary DES platforms.
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